Introduction
============

Angiofibroma of soft tissue is a recently described benign fibrovascular tumor of unknown cellular origin ([@b1-or-36-05-2455]). It arises most commonly in the extremities of middle-aged adults but displays a broad anatomic and age distribution. Microscopically, it is characterized by bland, uniform, probably fibroblastic spindle cell set in an abundant fibromyxoid stroma, with a prominent and highly characteristic vascular pattern composed of innumerable branching, thin-walled blood vessels ([@b1-or-36-05-2455]). Cytogenetic knowledge about angiofibroma of soft tissue is based on the analysis of six such tumors of which four showed a balanced t(5;8)(p15;q12) translocation and a fifth tumor showed a three-way t(5;8;8)(p15;q13;p11) ([@b1-or-36-05-2455]). Molecular analysis of four tumors carrying the t(5;8)(p15;q12) showed in-frame *AHRR*-*NCOA2* and *NCOA2*-*AHHR* fusion transcripts in all of them ([@b2-or-36-05-2455]). A *GTF2I*-*NCOA2* fusion gene was detected in a fifth tumor carrying a t(7;8;14)(q11;q13;q31) as the sole chromosome change ([@b3-or-36-05-2455]). To the best of our knowledge, the above-mentioned tumors are the only angiofibromas of soft tissue which have been investigated both cytogenetically and molecularly for fusion genes. An additional angiofibroma of soft tissue with t(5;8)(p15;q12) was also reported but without molecular analysis ([@b4-or-36-05-2455]). In three other studies, fluorescence *in situ* hybridization (FISH) was performed with probes for *NCOA2* showing rearrangements of the *NCOA2*; however, no further investigation of fusion genes was performed ([@b5-or-36-05-2455]--[@b7-or-36-05-2455]).

We report here an angiofibroma of soft tissue which had the chromosome translocations t(4;5)(q24;q31) and t(5;8;17)(p15;q13;q21) and identified the fusion genes generated by the two translocations. Our data show that, in addition to the reported *AHRR*-*NCOA2*, the tumor carried also other fusion genes resulting from the chromosomal aberrations that might have contributed to tumorigenesis as well.

Materials and methods
=====================

Ethics statement
----------------

The study was approved by the regional Ethics Committee (Regional komité for medisinsk forskningsetikk Sør-Øst, Norge; <http://helseforskning.etikkom.no>), and written informed consent was obtained from the patient to publication of the case details. The Ethics Committee\'s approval included a review of the consent procedure. All patient information has been de-identified.

Case history
------------

The patient was a 45-year-old male in whom MRI of the abdomen and pelvis showed a 53-mm tumor in the right inguinal region partially surrounding large vessels. The patient had been aware of the lesion for several years. Surgery was performed with removal of the entire tumor including part of the right deep femoral artery with immediate reconstruction of the vessel. The postoperative period was eventless and to date there is no sign of tumor relapse.

The specimen (58×45×45 mm) showed an encapsuled, well-circumscribed tumor with a homogenous gray/white cut surface. There were no signs of necrosis or bleeding. Routine microscopy showed a tumorous proliferation of small, spindled cells without atypia or mitotic activity ([Fig. 1A--C](#f1-or-36-05-2455){ref-type="fig"}). There were a lot of small, thin-walled blood vessels in the background ([Fig. 1A--C](#f1-or-36-05-2455){ref-type="fig"}). Immunohistochemical examination showed low proliferative activity (MIB1/Ki67 \<5%) ([Fig. 1D](#f1-or-36-05-2455){ref-type="fig"}) and the vessels highlighted by the endothelial marker CD34 ([Fig. 1E](#f1-or-36-05-2455){ref-type="fig"}). The clinical setting as well as histopathological features fit well with a diagnosis of angiofibroma of soft tissue ([@b1-or-36-05-2455]).

G-banding and karyotyping
-------------------------

Fresh tissue from the tumor was processed for cytogenetic analysis as part of our diagnostic routine. The sample was disaggregated mechanically and enzymatically with collagenase II (Worthington Biochemical Corp., Freehold, NJ, USA). The resulting cells were cultured and harvested using standard techniques. Chromosome preparations were G-banded with Wright stain and examined. The karyotype was written according to the International System for Human Cytogenetic Nomenclature (ISCN) 2013 guidelines ([@b8-or-36-05-2455]).

High-throughput paired-end RNA-sequencing
-----------------------------------------

Total RNA was extracted using miRNeasy Mini Kit according to the manufacturer\'s instructions (Qiagen, Hilden, Germany). Tumor tissue was disrupted and homogenized in QIAzol Lysis Reagent (Qiagen) using a 5-mm stainless steel bead and TissueLyser II (Qiagen). Subsequently, total RNA was purified using QIAcube (Qiagen). The RNA quality was evaluated using the Experion Automated Electrophoresis System (Bio-Rad Laboratories, Oslo, Norway). The RNA quality indicator (RQI) was 8.5. Total RNA (3 *µ*g) was sent for high-throughput paired-end RNA-sequencing at the Norwegian Sequencing Centre, Ullevål Hospital (<http://www.sequencing.uio.no/>). Detailed information about the high-throughput paired-end RNA-sequencing was given elsewhere ([@b9-or-36-05-2455]). The software FusionCatcher ([@b10-or-36-05-2455]) (<https://github.com/ndaniel/fusioncatcher>) was used for the discovery of fusion transcripts.

Molecular genetic analyses
--------------------------

The primers used for PCR amplification and sequencing are listed in [Table I](#tI-or-36-05-2455){ref-type="table"}. The primer combinations, target fusion transcripts, and results of PCR amplifications are shown in [Table II](#tII-or-36-05-2455){ref-type="table"}. cDNA was synthesized from 2 *µ*g of total RNA in a 20-*µ*l reaction volume using iScript Advanced cDNA Synthesis Kit for RT-qPCR according to the manufacturer\'s instructions (Bio-Rad Laboratories). cDNA was diluted to 100 *µ*l and 2 *µ*l were used as template in subsequent PCR assays. The 25-*µ*l PCR volumes contained 12.5 *µ*l of Premix Taq (Takara Bio Europe SAS, Saint-Germain-en-laye, France), 1 *µ*l of diluted cDNA, and 0.4 *µ*M of each of the forward and reverse primers ([Table II](#tII-or-36-05-2455){ref-type="table"}). The quality of the cDNA synthesis was examined by amplification of a cDNA fragment of the *TBCK* gene using the primers TBCK-2558F1 and TBCK-2908R1. The PCRs were run on a C1000 Thermal cycler (Bio-Rad Laboratories) with the following cycling for the amplifications: an initial denaturation at 94°C for 30 sec, 35 cycles of 7 sec at 98°C, 7 sec at 60°C, 1 min at 72°C, and a final extension for 5 min at 72°C.

The PCR products were analyzed on a QIAxcel Advanced System according to the manufacturer\'s instructions (Qiagen). The remaining PCR products were purified using the QIAquick PCR Purification Kit or the QIAquick Gel Extraction Kit (both from Qiagen) and direct sequenced using the dideoxy procedure with the ABI Prism BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) on the Applied Biosystems 3500 Genetic Analyzer sequencing system. The BLAST software (<http://www.ncbi.nlm.nih.gov/BLAST/>) was used for computer analysis of the sequence data.

Results
=======

Cytogenetic analysis
--------------------

The G-banding analysis showed that the tumor had two cytogenetically unrelated clones. The first clone, found in eight metaphases, had the t(4;5)(q24;q31) and t(5;8;17)(p15;q13;q21) chromosome aberrations ([Fig. 2A](#f2-or-36-05-2455){ref-type="fig"}). The second, found in two metaphases, had the t(1;14)(p31;q32) abnormality ([Fig. 2B](#f2-or-36-05-2455){ref-type="fig"}). This yielded the following karyotype: 46,XY,t(4;5)(q24;q31),t(5;8;17) (p15;q13;q21)\[8\]/46,XY,t(1;14)(p31;q32)\[2\]/46,XY\[3\].

High-throughput paired-end RNA-sequencing analysis
--------------------------------------------------

Using the FusionCatcher software with the FASTQ files obtained from the Norwegian Sequencing Centre, Ullevål Hospital (<http://www.sequencing.uio.no/>), 39 potential fusions were found: 28 fusions were described as readthrough short-distance fusions and 5 as pseudogenes ([Table III](#tIII-or-36-05-2455){ref-type="table"}). Among the other fusions, the program detected the *P4HA2*-*TBCK* and the reciprocal *TBCK*-*P4HA2*. According to the UCSC genome Browser on Human, Feb. 2009, (GRCh37/hg19) assembly ([http://genome-euro.ucsc.edu/cgi-bin/hggateway](http://genome-euro.ucsc.edu/cgi-bin/hgGateway)), *P4HA2* maps on chromosome subband 5q31.1 and *TBCK* on band 4q24. Thus, the two fusions *P4HA2*-*TBCK* and the reciprocal *TBCK*-*P4HA2* most probably were the result of the balanced chromosome translocation t(4;5)(q24;q31). FusionCatcher also detected *AHRR*-*NCOA2* and *ETV4*-*AHRR* which correspond to the three-way t(5;8;17)(p15;q13;q21) found in the tumor. The three genes *AHRR*, *NCOA2*, and *ETV4* map to chromosome subbands 5p15.33, 8q13.3, and 17q21.31, respectively (<https://genome.ucsc.edu/>). In the three-way t(5;8;17), the moving of 5p15 to 8q13 generated the *AHRR*-*NCOA2* fusion whereas the translocation of 17q21 to 5p15 generated the *ETV4*-*AHRR*. We assume that the moving of 8q13 to 17q21 would have generated an *NCOA2*-*ETV4* fusion but no such fusion was, for unknown reasons, detected by FusionCatcher. The fusion transcrips *EGFL7*-*MCF2L* and a *CYP1B1*-*CLU* were also detected by the analysis with FusionCatcher, in all likelihood generated by t(9;13)(q34;q34) and t(2;8)(p22.2;p21.1), respectively. No fusion gene corresponding to the cytogenetically detected t(1;14)(p31;q32) was found.

We decided to investigate with molecular methods the described fusion transcripts. No other fusions were examined.

Molecular genetic confirmation of fusions
-----------------------------------------

PCR with the primers TBCK-2558F1 and TBCK-2908R1 amplified a cDNA of the *TBCK* gene indicating that the synthesized cDNA was of good quality.

RT-PCR using cDNA from the tumor and subsequent direct Sanger sequencing verified the presence of the *P4HA2*-*TBCK*, *TBCK*-*P4HA2*, *AHRR*-*NCOA2*, *ETV4*-*AHRR*, and *NCOA2*-*ETV4* fusion transcripts ([Table II](#tII-or-36-05-2455){ref-type="table"} and [Fig. 3](#f3-or-36-05-2455){ref-type="fig"}). *TBCK*-*P4HA2*, *AHRR*-*NCOA2*, and *NCOA2*-*ETV4* were in-frame fusions which would code for chimeric proteins. The detected *ETV4*-*AHRR* fusion, on the other hand, was out-of-frame and would not produce a chimeric protein, nor would the *P4HA2*-*TBCK* code for any functional protein. No *EGFL7*-*MCF2L* or *CYP1B1*-*CLU* fusion transcript was found by RT-PCR amplification ([Table II](#tII-or-36-05-2455){ref-type="table"}).

Discussion
==========

The examined angiofibroma of soft tissue carried the recurrent *AHRR*-*NCOA2* fusion transcript but lacked the reciprocal *NCOA2*-*AHRR*. This finding supports the initial suggestion that *AHRR*-*NCOA2* is the pathogenetically significant fusion transcript in tumors carrying a t(5;8)(p15;q12) ([@b2-or-36-05-2455],[@b3-or-36-05-2455]). While we were examining the current tumor, a report was published describing 13 cases of angiofibroma of soft tissue with an *AHRR*-*NCOA2* but with only eight of them carrying the reciprocal *NCOA2*-*AHRR* ([@b11-or-36-05-2455]). Current data therefore agree that the *AHRR*-*NCOA2* fusion gene is recurrent in angiofibroma of soft tissue \[([@b2-or-36-05-2455],[@b3-or-36-05-2455],[@b11-or-36-05-2455]), present case\] and indicate that this is the pathogenetically crucial outcome of the t(5;8).

Using FISH on formalin-fixed, paraffin-embedded specimens, Sugita *et al* ([@b5-or-36-05-2455]) found that 16--36% of the tumor cells showed *NCOA2* rearrangement. A fairly small proportion of *NCOA2* gene rearrangement-positive cells (4--12 split signals per 50 tumor cell nuclei) was recently reported also by Yamada *et al* ([@b11-or-36-05-2455]). The split signals were mostly detected in relatively large, spindle-shaped nuclei, indicating that these were the ones belonging to the neoplastic parenchyma ([@b11-or-36-05-2455]).

The present tumor had two cytogenetically unrelated clones: one (eight metaphases) with the translocations t(4;5)(q24;q31) and t(5;8;17)(p15;q13;q21) and another (2 cells) with t(1;14)(p31;q32) as the sole chromosome abnormality. Thus, our data not only are in agreement with previous observations that only a fraction of tumor cells carry the *NCOA2* gene rearrangement, but also demonstrate genetic heterogeneity of uncertain pathogenetic significance within the tumor. Although no fusion gene was found corresponding to t(1;14)(p31;q32), this should not lead us to conclude that the translocation was pathogenetically unimportant. The t(1;14)(p31;q32) chromosome aberration may exert its influence through a position effect causing deregulation of a gene in the proximity of the breakpoints. Alternatively, the current methodology may be unable to detect a fusion gene as has been demonstrated ([@b9-or-36-05-2455]).

So far, three types of *AHRR*-*NCOA2* fusion transcripts have been described: in the first type, exon 9 of *AHRR* is joined with exon 16 of *NCOA2*, the second type shows exon 10 of *AHRR* being joined to exon 14 of *NCOA2*, and in the third type there is an insertion of an intronic sequence from the *NCOA2* gene between exon 9 of *AHRR* and exon 14 of *NCOA2* ([@b2-or-36-05-2455],[@b11-or-36-05-2455]). In the present angiofibroma of soft tissue, two novel fusion transcripts were found with different fusion positions from those previously described: a fusion transcript in which nt 1670 (sequence with accession no. NM_020731) from exon 12 of the *AHRR* gene was fused with a sequence from intron 14 of *NCOA2* and a transcript in which nt 1533 (also from exon 12) of *AHRR* was fused to exon 15 of *NCOA2* (sequence with accession no. NM_006540.2). The resulting putative AHRR-NCOA2 protein would be similar to those reported ([@b2-or-36-05-2455]) in as much as the C-terminal part of AHRR is replaced by the C-terminal part of NCOA2.

The involvement of *NCOA2* in neoplasia was first reported in acute myeloid leukemia with the cytogenetic inversion inv([@b8-or-36-05-2455])(p11q13) which resulted in a *KAT6A*-*NCOA2*, also known as *MOZ*-*TIF2* fusion gene ([@b12-or-36-05-2455],[@b13-or-36-05-2455]). Since then, *NCOA2* has been implicated also in other malignancies. A fusion between *ETV6* (*TEL*) and *NCOA2* was reported in childhood leukemia with the recurrent t(8;12)(q13;p13) ([@b14-or-36-05-2455]). A *PAX3*-*NCOA2* gene was found as a rare variant fusion in alveolar rhabdomyosarcoma; it was brought about by a t(2;8)(q35;q13) translocation ([@b15-or-36-05-2455]). A *HEY1*-*NCOA2* fusion gene was described in mesenchymal chondrosarcomas ([@b16-or-36-05-2455],[@b17-or-36-05-2455]). Recently, *SRF*-*NCOA2*, *TEAD1*-*NCOA2*, and *VGLL2*-*NCOA2* fusions were reported in rhabdomyosarcomas ([@b18-or-36-05-2455],[@b19-or-36-05-2455]). In all the above-mentioned fusions, *NCOA2* is the 3′-partner gene and all fusion proteins contain the two C-terminal activation domains AD1/CID (activation domain 1/CREB-binding protein interacting domain) and AD2 ([@b2-or-36-05-2455],[@b3-or-36-05-2455],[@b12-or-36-05-2455]--[@b19-or-36-05-2455]). The transforming activities of *KAT6A*-*NCOA2* and *PAX3*-*NCOA2* have been demonstrated experimentally ([@b15-or-36-05-2455],[@b20-or-36-05-2455]). In addition, *KAT6A*-*NCOA2* was shown to induce acute myeloid leukemia in transgenic fish ([@b21-or-36-05-2455]). Deguchi *et al* ([@b20-or-36-05-2455]) showed that the *KAT6A*-*NCOA2* interaction with CREBBP through AD1/CID is essential for transformation. Similarly, Sumegi *et al* ([@b15-or-36-05-2455]) showed that while deletion of the AD2 portion of PAX3-NCOA2 fusion protein reduced the transforming activity, deletion of the AD1/CID domain fully abrogated the transforming activity of the chimeric protein. Thus, the AD1/CID and AD2 domains of NCOA2 seem to be essential for the transformation ability of the various fusion proteins.

The three-way translocation t(5;8;17)(p15;q13;q21) of the present case not only generated an *AHRR*-*NCOA2* resulting from the translocation of 5p15 to 8q13, but also two additional fusion genes: an *NCOA2*-*ETV4*, stemming from the moving of 8q13 to 17q21, and an *ETV4*-*AHRR*, generated by the moving of 17q21 to 5p15. The detected *ETV4*-*AHRR* fusion transcript is out-of-frame and so cannot produce a chimeric protein. The *NCOA2*-*ETV4* fusion transcript is in-frame coding for a chimeric NCOA2-ETV4 protein, the oncogenetic potential of which cannot be ruled out. Based on the NCOA2 and ETV4 proteins with accession nos. NP_006531.1 and NM_001986.2, respectively, the chimeric NCOA2-ETV4 would contain 1,175 amino acids. The NCOA2 N-terminal part of the protein would contain the helix-loop-helix, PAS_9 and PAS_11, the CITED, and the SRC-1 domains. The ETV4 C-terminal part would contain the ETS DNA-binding domain of ETV4 ([Fig. 4](#f4-or-36-05-2455){ref-type="fig"}).

ETV4 was reported to contribute the 3′-part of the oncogenic protein in the subset of Ewing\'s sarcomas characterized by a t(17;22)(q12;q12) translocation ([@b22-or-36-05-2455],[@b23-or-36-05-2455]). The EWSR1-ETV4 protein, in which the N-terminal part of EWSR1 is fused to the ETS DNA-binding domain of ETV4, has an oncogenetic potential similar to that of the EWSR1-FLI1, EWSR1-ERg, EWSR1-FEV, and EWSR1-ETV1 fusion proteins which may also be found in Ewing\'s sarcoma ([@b24-or-36-05-2455]). The *ETV4* gene was also described as the 3′-partner in fusion genes found in prostate carcinoma ([@b25-or-36-05-2455]--[@b27-or-36-05-2455]). *ETV4* was found to fuse with the *TMPRSS2*, *KLK2*, *CANT1*, and *DDX5* ([@b25-or-36-05-2455]--[@b27-or-36-05-2455]). All these fusions genes, *TMPRSS2*-*ETV4*, *KLK2*-*ETV4*, *CANT1*-*ETV4*, and *DDX5*-*ETV4*, contain (like the present *NCOA2*-*ETV4*) the part of ETV4 coding for the ETS DNA-binding domain.

The chromosome translocation t(4;5)(q24;q31) generated the *P4HA2*-*TBCK* and *TBCK*-*P4HA2* fusion transcripts. *P4HA2*-*TBCK* does not encode any functional protein, whereas *TBCK*-*P4HA2* encodes a chimeric 1,335-amino acid protein. TBCK-P4HA2 would contain the first 794 out of 830 amino acids of the TBCK protein (accession no. NP_149106.2), 6 amino acids from the untranslated region of exon 2 of P4HA2 (accession no. NM_004199.2), and the entire 535 amino acid-P4HA2 protein (NP_004190.1). The function of this putative chimeric protein is difficult to predict since it would contain both the protein kinase domain, the Rhodanese-like domain, and the Tre-2/Bub2/Cdc16 (TBC) domain of TBCK together with the P4HA2 protein which is a component of the prolyl 4-hydroxylase. The TBCK protein is thought to play a role in actin organization, cell growth, and cell proliferation by regulating the mammalian target of the rapamycin (mTOR) signaling pathway. This protein may also be involved in the transcriptional regulation of the components of the mTOR complex (<http://www.ncbi.nlm.nih.gov/gene/93627>). Depletion of TBCK significantly inhibits cell proliferation, reduces cell size, and disrupts the organization of actin but not microtubule. Knockdown of TBCK induces a significant decrease in the protein levels of components of mTOR complex (mTORC) and suppresses the activity of mTOR signaling, but not the MAPK or PDK1/Akt pathway ([@b28-or-36-05-2455]).

The protein encoded by the *P4HA2* gene is one of several different types of α subunit of the prolyl 4-hydroxylase and provides the major part of the catalytic site of the active enzyme (<http://www.ncbi.nlm.nih.gov/gene/8974>). In collagen and related proteins, prolyl 4-hydroxylase catalyzes the formation of 4-hydroxyproline that is essential to the proper three-dimensional folding of newly synthesized procollagen chains. In breast cancer, P4HA2 was shown to promote progression and metastasis by regulating collagen deposition ([@b29-or-36-05-2455]). In squamous cell carcinoma of the oral cavity, P4HA2 was identified as a metastasis associated protein ([@b30-or-36-05-2455]).

In spite of the now repeatedly documented recurrence of *AHRR*-*NCOA2* in angiofibroma of soft tissue \[present case, ([@b2-or-36-05-2455],[@b11-or-36-05-2455])\], our findings indicate that also additional genetic events, some of which lead to fusion genes, may be important in tumor development. Worthy of mention is that of the eight hitherto cytogenetically reported tumors, including the present case, three had three-way translocations ([@b1-or-36-05-2455]--[@b3-or-36-05-2455]). What lies behind this highly unusual feature is unknown. Obviously, more such tumors must be studied cytogenetically and molecularly before all important aspects of their pathogenesis are laid bare.
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![Microscopic examination of the angiofibroma of soft tissue. (A) H&E-100×. (B) H&E-200×. (C) H&E-400×. (D) Immunoexpression of MIB1-200×. (E) Immunoexpression of CD34-200×.](OR-36-05-2455-g00){#f1-or-36-05-2455}

![Cytogenetic analysis of the angiofibroma of soft tissue. (A) Partial karyotype showing from left to right the chromosomes 4, der([@b4-or-36-05-2455])t(4;5) (q24;q31), der([@b5-or-36-05-2455])t(4;5)(q24;q31), der([@b5-or-36-05-2455])t(5;8;17)(p15;q13;q21), 8, der([@b8-or-36-05-2455])t(5;8;17) (p15;q13;q21), der([@b17-or-36-05-2455])t(5;8;17)(p15;q13;q21), and 17. (B) Partial karyotype showing the der([@b1-or-36-05-2455])t(1;14)(p31;q32) and der([@b14-or-36-05-2455])t(1;14)(p31;q32) together with the corresponding normal chromosome homologs. Breakpoint positions are indicated by arrows.](OR-36-05-2455-g01){#f2-or-36-05-2455}

![Partial sequence chromatogram of the amplified cDNA fragment showing the junction points of the fusion transcripts. (A) *P4HA2*-*TBCK*, (B) *TBCK*-*P4HA2*, (C) exon 12 of *AHRR* with sequence of intron 14 of *NCOA2*, (D) exon 12 of *AHRR* with exon 14 of *NCOA2*, (E) *ETV4*-*AHRR*, and (F) *NCOA2*-*ETV4*.](OR-36-05-2455-g02){#f3-or-36-05-2455}

![Illustration of the proteins AHRR, NCOA2, AHRR-NCOA2, NCOA2-ETV4, and TBCK-P4H2A. The domains, their accession nos., and intervals are also shown. Arrows in the AHRR protein indicate the known fusion points for the published AHRR-NCOA2 proteins. Arrows in the AHRR-NCOA2, NCOA2-ETV4, and TBCK-P4H2A show the fusion points in the present angiofibroma of soft tissue.](OR-36-05-2455-g03){#f4-or-36-05-2455}

###### 

Primers used for PCR amplification and Sanger sequencing analyses.

  Name              Sequence (5′→3′)           Position             Reference sequence   Gene
  ----------------- -------------------------- -------------------- -------------------- ----------
  TBCK-2908R1       TGGCGTGGATATGAAGAACTGTGC   2931--2908           NM_033115.4          *TBCK*
  TBCK-2558F1       CCTGGTGGTTGACATCCGGAATAG   2558--2581           NM_033115.4          *TBCK*
  P4HA2-785R1       AGCCAGGTAGCCCTCAGCATCAG    807--785             NM_004199.2          *P4HA2*
  P4HA2-33F1        CCGCGGGAGGTTCTGGAAAC       33--52               NM_001142598.1       *P4HA2*
  NCOA2-intr14-R1   CACCATGTCGAGACTGCTGGCTC    71106777--71106799   NC_018919.2          *NCOA2*
  NCOA2-3364R1      TCACTCGGAGACTCAGCTGCAGG    3386--3364           NM_006540.2          *NCOA2*
  NCOA2-2858F1      CTGGACCTTTCCCACCAATCAGAA   2858--2881           NM_006540.2          *NCOA2*
  ETV4-1496R1       GGGGCTCTCATCCAAGTGGGAC     1517--1496           NM_001986.2          *ETV4*
  ETV4-863F1        TGGGGTCAATGGGCACAGGTAC     863--884             NM_001986.2          *ETV4*
  AHRR-1932R1       TGCAGGGTGGAAAGGGGTCAG      1952--1932           NM_020731.4          *AHRR*
  AHRR-1503F1       AGCAGACCCATGCGGGATGTC      1503--1523           NM_020731.4          *AHRR*
  AHRR-1425F1       TGTGTCCAGGGCACTTTCAGGAA    1425--1447           NM_020731.4          *AHRR*
  EGFL7-353F1       ACCCCAAAGCCACATCTGTAGCC    353--375             NM_016215.4          *EGFL7*
  MCF2l-3271R1      CGCCACGACCGTGTATTTACCTG    3293--3271           NM_024979.4          *MCF2L*
  CYP1B1-132F1      TCAACGCTGTGAGGAAACCTCGA    132--154             NM_000104.3          *CYP1B1*
  CLU-1164R1        GACCTGGAGGGATTCGTCGAGC     1185--1164           NM_001831.3          *CLU*

###### 

Primer combinations, target fusion transcripts and results of PCR amplification.

  Primer combination            Target fusion transcripts   Results
  ----------------------------- --------------------------- ----------
  P4HA2-33F1/TBCK-2908R1        *P4HA2*-*TBCK*              Positive
  TBCK-2558F1/P4HA2-785R1       *TBCK*-*P4HA2*              Positive
  AHRR-1503F1/NCOA2-intr14-R1   *AHRR*-*NCOA2*              Positive
  AHRR-1425F1/NCOA2-3364R1      *AHRR*-*NCOA2*              Positive
  ETV4-863F1/AHRR-1932R1        *ETV4*-*AHRR*               Positive
  NCOA2-2858F1/ETV4-1496R1      *NCOA2*-*ETV4*              Positive
  EGFL7-353F1/MCF2L-3271R1      *EGFL7*-*MCF2L*             Negative
  CYP1B1-132F1/CLU-1164R1       *CYP1B1*-*CLU*              Negative

###### 

Fusion transcripts detected using FusionCatcher.

  5′-Partner gene   3′-Partner gene   Fusion description   Fusion sequence
  ----------------- ----------------- -------------------- ----------------------------------------------------------
  *PCDP1*           *TMEM177*         Readthrough          ATTCTAGAATGAAAGTCACCAGTAG\*gaaagggaacatcacagaaaggtga
  *MIR155HG*        *JAM2*            Readthrough          CAAGGAGACGCTCCTGGCACTGCAG\*atcataaggcctatgggttttctgc
  *GOLT1A*          *KISS1*           Readthrough          ATGATCTCCATCACCGAATGGCAGA\*cctcaaggcacttctaggacctgcc
  *SHISA9*          *U91319.1*        Readthrough          AAGTACGCCTCCTTAAAGGCAGTCG\*agctggaacacccttcttctcctgc
  *VPS45*           *PLEKHO1*         Readthrough          GCACCACAGTGCACAACACGAAAAG\*ggacctcaggatggaaaccagcagc
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